Entest BioMedical Announces Creation of Proprietary Adult Stem Cell Lines
To Serve as Platform for Screening of Regenerative Photoceuticals
March 08, 2010: 08:00 AM ET
Entest BioMedical Inc. (OTCBB: ENTB) announced today the creation of 3 bone marrow derived stem cell lines useful for optimizing laser intensities and wavelengths in laser enhanced stem cell therapy. A stem cell line is a defined cell population that is derived from a single cell and has the capability to replicate for long periods of time in vitro. Proprietary stem cell lines are commonly licensed for various applications ranging from research to product development.
The Company believes the development of these stem cell lines will assist in the progress of its stem cell therapy for COPD treatment.
These cells, ENT-CL101, ENT-CL221, and ENT-CL303, similar in nature to mesenchymal stem cells, are stable in cell culture, and can be expanded en masse for wide-scale screening.
"The creation of a standardized platform for assessing light-based therapies in vitro allows for mass screening for specific biological properties in the same way that drug companies screen small molecules," said Dr. Feng Lin, Director of Research and Development. "This is unique not only in the fact that we are using lasers instead of drugs for screening, but also that the targets are stem cell lines. The cell lines we have developed are also potentially useful for Pharmaceutical companies to screen agents that activate stem cells."
The traditional model of drug discovery involves screening thousands to millions of compounds in vitro on cells that represent the disease state. For example, if one is developing cancer therapeutics, the cancer cells are treated with random compounds and the compounds that kill the cells in vitro are chosen for animal testing. The creation of ENT-CL101, ENT-CL221, and ENT-CL303 allows for the same approach to be used in the area of light therapy. To date identification of appropriate frequencies and intensities for therapy is based on direct testing in animals, which is extremely costly.
The platform developed by Entest is anticipated to substantially save the cost of therapeutics development in the area of regenerative photoceuticals.
"We are extremely proud of the out of the box approach that our scientists have developed, which basically takes the area of laser-based therapy into the 21st Century drug development arena," said David Koos, Chairman and CEO of Entest.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576TM is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.